Study shows additional role for abiraterone in blocking tumor growth in CRPC
As part of an EU-supported IMI-PREDECT consortium (http://www.predect.eu), a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of ca ...
Cancer
Mar 15, 2013 |
not rated yet |
0
Prostate cancer lifetime risk trebles in 25 years
Boys born in 2015 will have almost three times the risk of being diagnosed with prostate cancer at some point during their lives than those born in 1990.
Cancer
Jan 23, 2013 |
not rated yet |
0
Abiraterone benefits chemo-naive with advanced prostate CA
(HealthDay)—For chemotherapy-naive patients with metastatic castration-resistant prostate cancer, abiraterone acetate correlates with improved radiographic progression-free survival, according to a study ...
Cancer
Dec 12, 2012 |
not rated yet |
0
Longer life expectancy, aging population necessitate new strategies for prostate cancer care
The population of the United States is getting older, due not only to aging boomers but also to a four-year increase in life expectancy from 1990 to 2010. An aging population means increased diagnosis of prostate cancer. ...
Cancer
Dec 04, 2012 |
not rated yet |
0
Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer ...
Cancer
Sep 17, 2012 |
not rated yet |
0
Baseline hormone levels may predict survival in metastatic, castration-resistant prostate cancer
Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according ...
Cancer
Apr 03, 2012 |
not rated yet |
0
Abiraterone: Indication of considerable added benefit in certain patients
Abiraterone (trade name: Zytiga) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic ...
Medications
Jan 06, 2012 |
not rated yet |
0
